ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 125 filers reported holding ANAPTYSBIO INC in Q2 2020. The put-call ratio across all filers is 7.78 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $647,045 | -11.7% | 36,027 | -0.0% | 0.00% | 0.0% |
| Q2 2023 | $733,135 | -97.5% | 36,044 | -97.3% | 0.00% | -97.3% |
| Q1 2023 | $29,153,134 | -60.4% | 1,339,758 | -43.5% | 0.07% | -64.0% |
| Q4 2022 | $73,539,983 | +21.5% | 2,373,023 | +0.0% | 0.20% | +14.7% |
| Q3 2022 | $60,533,000 | +29.4% | 2,372,923 | +3.0% | 0.18% | +39.4% |
| Q2 2022 | $46,773,000 | +17.9% | 2,304,097 | +43.7% | 0.13% | +41.1% |
| Q1 2022 | $39,663,000 | -28.9% | 1,603,187 | -0.1% | 0.09% | -13.5% |
| Q4 2021 | $55,749,000 | +118.2% | 1,604,287 | +70.3% | 0.10% | +112.2% |
| Q3 2021 | $25,554,000 | +9.1% | 942,273 | +4.3% | 0.05% | +11.4% |
| Q2 2021 | $23,425,000 | -4.0% | 903,407 | -20.2% | 0.04% | -6.4% |
| Q1 2021 | $24,400,000 | -14.0% | 1,132,268 | -14.2% | 0.05% | -19.0% |
| Q4 2020 | $28,365,000 | +36.8% | 1,319,284 | -6.2% | 0.06% | +18.4% |
| Q3 2020 | $20,739,000 | -34.4% | 1,406,033 | -0.7% | 0.05% | -37.2% |
| Q2 2020 | $31,618,000 | +75.7% | 1,415,310 | +11.1% | 0.08% | +47.2% |
| Q1 2020 | $17,998,000 | -53.4% | 1,273,767 | -46.4% | 0.05% | -38.4% |
| Q4 2019 | $38,647,000 | -16.6% | 2,378,300 | +79.6% | 0.09% | -24.6% |
| Q3 2019 | $46,330,000 | -29.4% | 1,324,100 | +13.9% | 0.11% | -28.3% |
| Q2 2019 | $65,611,000 | +38.3% | 1,162,900 | +79.0% | 0.16% | +35.9% |
| Q1 2019 | $47,455,000 | +21.0% | 649,620 | +5.7% | 0.12% | +9.3% |
| Q4 2018 | $39,207,000 | -28.2% | 614,620 | +12.4% | 0.11% | -15.7% |
| Q3 2018 | $54,574,000 | +56.3% | 547,000 | +11.3% | 0.13% | +24.5% |
| Q2 2018 | $34,909,000 | -24.0% | 491,400 | +11.4% | 0.10% | -23.3% |
| Q1 2018 | $45,923,000 | +3.4% | 441,230 | +0.0% | 0.13% | +6.4% |
| Q4 2017 | $44,430,000 | +661.2% | 441,128 | +164.1% | 0.12% | +635.3% |
| Q3 2017 | $5,837,000 | +22.0% | 167,000 | -16.5% | 0.02% | +21.4% |
| Q2 2017 | $4,786,000 | -13.8% | 200,000 | 0.0% | 0.01% | -12.5% |
| Q1 2017 | $5,550,000 | – | 200,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |